Effects of physical exercise on neurofilament light chain in multiple sclerosis and other neurological disorders: A systematic review.

Mult Scler Relat DisordJun 29, 2026 (epub)
Clinical ResearchNeurology

Alberto De León-Muñoz, Jacobo Á Rubio-Arias, Vicente Ávila-Gandía et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effects of physical exercise on neurofilament light chain (NfL) levels in individuals with multiple sclerosis (MS) and other neurological disorders. The analysis included 15 studies with 765 patients, primarily focusing on MS. Significant reductions in NfL were observed following resistance training, Pilates, and high-intensity interval training (HIIT) in MS patients, while other exercise types showed no significant effects.

Key findings

  • In MS, resistance training, Pilates, and HIIT significantly reduced NfL concentrations.
  • Prolonged moderate-to-high intensity aerobic exercise had no significant effects on NfL in MS or other disorders.
  • Resistance-based programs also led to reductions in GFAP and tau protein levels.

Why it matters

Understanding the impact of exercise on biomarkers like NfL can inform treatment strategies for neurodegenerative diseases. This knowledge may help clinicians recommend specific exercise modalities to potentially enhance neuroprotection in patients with MS.

Source

PubMed · PMID 42413317

Published in Mult Scler Relat Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.